Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Read more about Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.
Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans. Read more about Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans.
Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. Read more about Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks.
Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma. Read more about Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Read more about A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.
Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Read more about Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Read more about Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Translation control of the immune checkpoint in cancer and its therapeutic targeting. Read more about Translation control of the immune checkpoint in cancer and its therapeutic targeting.
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Read more about Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Read more about Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
